Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene's Focus On Execution Pays Off, But Follow-Through Is Key

Executive Summary

Third quarter sales grew 18.5% to $3.89bn, beating consensus with Otezla's contribution of 40.3% growth. After several disappointments, Celgene appears to be back on track with efforts to boost revenue before Revlimid generics hit in 2022.

Advertisement

Related Content

Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?
Celgene’s Positive Phase III Data For Otezla In Scalp Psoriasis Could Yield Broader Label
Bluebird's BCMA CAR-T Sings At ASCO, But How Will It Fly In Early Multiple Myeloma?
Celgene's Terrie Curran On Building, Broadening The I&I Franchise
Arena Ready For Etrasimod Phase III Face-Off With Celgene's Ozanimod In UC
Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy
Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond
Celgene's CAR-T Leadership Goals Advance At ASH 2017
Celgene Admits It Screwed Up Otezla Estimates; Investors Lose Confidence
Celgene IBD Pipeline In Question As Mongersen Crohn’s Disease Trial Ends

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124060

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel